Live Breaking News & Updates on Clinical development centers

Stay updated with breaking news from Clinical development centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Beijing , Guangzhou , Guangdong , Shanghai , Boston , Massachusetts , United-states , Suzhou , Jiangsu , Hangzhou , Zhejiang

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

China , Shanghai , Hangzhou , Zhejiang , Suzhou , Jiangsu , Princeton , Massachusetts , United-states , Beijing , Guangzhou , Guangdong

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

South-korea , China , Suzhou , Jiangsu , Princeton , Massachusetts , United-states , Shanghai , Hangzhou , Zhejiang , Boston , Guangzhou

Transcenta to Present Three Study Results at ESMO 2023

Transcenta to Present Three Study Results at ESMO 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Spain , China , Hangzhou , Zhejiang , Beijing , Suzhou , Jiangsu , Boston , Massachusetts , United-states , Guangzhou , Guangdong

Transcenta To Present Three Study Results At Esmo 2023

Transcenta To Present Three Study Results At Esmo 2023
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Spain , Guangzhou , Guangdong , China , Lin-shen , Shanghai , Madrid , Hangzhou , Zhejiang , Princeton , Massachusetts , United-states

Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

United-states , Princeton , Massachusetts , Hangzhou , Zhejiang , China , Beijing , Suzhou , Jiangsu , Boston , Shanghai , Guangzhou

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

South-korea , China , Beijing , Shanghai , Hangzhou , Zhejiang , Princeton , Massachusetts , United-states , Guangzhou , Guangdong , Boston

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

China , Beijing , Boston , Massachusetts , United-states , Guangzhou , Guangdong , Shanghai , Princeton , Suzhou , Jiangsu , Hangzhou

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Beijing , Suzhou , Jiangsu , Hangzhou , Zhejiang , Boston , Massachusetts , United-states , Guangzhou , Guangdong , Shanghai

Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.

/PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2023 ASCO Business Update Call conference on June 7, 2023....

Hangzhou , Zhejiang , China , Shanghai , Guangzhou , Guangdong , Boston , Massachusetts , United-states , Princeton , Suzhou , Jiangsu